Researchers at the University of Cincinnati College of Medicine have identified a previously unknown mechanism by which skeletal muscle absorbs glucose from the blood without requiring insulin, according to a study published in the Nature Portfolio journal Communications Biology. The discovery could eventually lead to new treatments for diabetes, hyperglycemia and insulin resistance that target this pathway directly in muscle tissue.

The newly identified pathway, named mSGLT, shares properties with SGLT2 — the glucose transporter in the kidneys that is targeted by widely used drugs such as Jardiance (empagliflozin). Unlike those drugs, which lower blood sugar by prompting the kidneys to excrete excess glucose in urine, a therapy aimed at mSGLT would work by increasing glucose uptake in skeletal muscle itself.

“This insulin-independent process uses a glucose transport protein in skeletal muscle and may offer a drug target for controlling blood sugar,” said Judith A. Heiny, PhD, professor emerita in the Division of Neurobiology and Integrative Physiology at UC and the study’s co-corresponding author, in a university news release. “The skeletal musculature is the natural depot for glucose. It has a huge capacity to regulate blood sugar, which can be a struggle for those with diabetes and insulin resistance.”

Skeletal muscle accounts for about 40% of human body mass and plays a central role in blood glucose regulation. After a meal, rising insulin signals muscles to absorb and store up to 90% of ingested glucose through a transport protein called GLUT4. During exercise or stress, however, insulin levels drop — yet working muscles can absorb glucose at rates up to 100 times higher than after a meal to meet energy demands. How muscles accomplish this without insulin has remained a puzzle despite decades of research, the university noted.

For people with insulin resistance or diabetes, whose muscles respond less effectively to insulin and clear glucose more slowly, this newly understood pathway could be especially relevant. “A therapy that targets glucose uptake by skeletal muscles could be as impactful as SGLT2 inhibitors that lower blood sugar by stimulating the kidneys to excrete excess glucose in the urine,” said Natalie Norman, PhD, the study’s first author, who contributed as a UC graduate student and is now a postdoctoral researcher at the Karolinska Institute in Stockholm, Sweden.

To identify the mSGLT pathway, researchers at the University of Cincinnati initially needed to create a method for gauging glucose absorption in muscle tissue in the absence of insulin. Employing glucose variants that are carried by SGLT-type transporters but not by GLUT4 proteins, they examined muscles taken from animal models and used electrical stimulation to induce contractions that replicate active muscle. “We showed that if we stimulate muscle to contract in insulin-free conditions, it can take up a lot of glucose from a pathway that’s not GLUT4,” Heiny said.

Working with collaborators at the Icahn School of Medicine at Mount Sinai, the team also developed a new technique to measure glucose uptake using inductively coupled plasma mass spectroscopy (ICP-MS). “I expect our method will be ideal for studying biological processes that require simultaneous tracking of multiple molecules,” said Julio Landero, PhD, co-corresponding author and associate professor and director of a trace metals lab at Mount Sinai.

The next phase of research will focus on identifying the specific protein responsible for mSGLT glucose uptake and determining whether targeting the pathway can improve blood sugar regulation. “This study defines the core properties of mSGLT in muscle. Studies are underway to identify the gene and protein at the molecular level,” Heiny said.

The research received funding from the National Institutes of Health, the UC College of Medicine, and private philanthropy. Co-authors comprised Tatiana L. Radzyukevich and Bryan Mackenzie from UC; former UC undergraduate Tiffany Zhu; Peter W. Chomczynski and Michal Rymaszewski, previously with Molecular Research Center Inc. in Cincinnati; Izabela Fokt and Waldemar Priebe from the University of Texas MD Anderson Cancer Center; and Lucas Schmidt from Mount Sinai..

For university students, particularly those studying biomedical sciences, medicine or physiology, the finding illustrates how fundamental research into basic biological mechanisms can uncover potential therapeutic targets. The work also highlights the role of graduate and postdoctoral researchers — Norman conducted the research as a UC graduate student — in driving significant discoveries. Students interested in diabetes research or metabolic disease may want to follow the ongoing efforts to identify the mSGLT gene and protein, as those steps will determine whether the pathway can be translated into a drug target.